Sunday, 20 September 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

ABL Diagnostics Stock Bearish Momentum With A 33% Slide In The Last 21 Sessions

Loading stream...

(vianews) - shares of abl diagnostics (cac 40: abld.pa) dropped by a staggering 33.33% in 21 sessions from €8.7 to €5.80 at 05:36 est on tuesday, after five successive sessions in a row of losses. cac 40 is jumping 0.05% to €7,418.21, after three consecutive sessions in a row of gains.

about abl diagnostics

abl diagnostics société anonyme does not have significant operations. the company was formerly known as etablissements fauvet girel and changed its name to abl diagnostics société anonyme in april 2022. the company is headquartered in paris, france. abl diagnostics société anonyme is a subsidiary of advanced biological laboratories (abl) s.a.

earnings per share

as for profitability, abl diagnostics has a trailing twelve months eps of €-0.08.

more news about abl diagnostics (abld.pa).

Categories

stockMarket

Tags

ABL DiagnosticsStock PricePrice DownMarket Session NowStock Price DownStock Market NowABLD.PAMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com